Figure 4 — Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis

Navigate

Research Paper|Volume 13, Issue 11|pp. 15413–15432

100%

Figure 4.Progression-free survival hazard ratio in female patients in the immune checkpoint inhibitor group compared with the control group.

Figure 4 — Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis | Aging